Compare DexCom, Inc. (DXCM) vs iShares MSCI Hong Kong ETF (EWH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares MSCI Hong Kong ETF — how do they compare? DexCom, Inc. trades at $83.9 (market cap $31.86B), while iShares MSCI Hong Kong ETF trades at $22.05 (market cap $1.16B). The key difference: DexCom, Inc. is far larger — about 27.5× iShares MSCI Hong Kong ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares MSCI Hong Kong ETF for 61 Days on average.
| DXCM | EWH | |
|---|---|---|
Market Cap | $31.86B | $1.16B |
Volume | 3,607,070 | 3,176,523 |
Sector | Health | Broad Market / Factor |
52-Week High | $92.34 | $24.55 |
52-Week Low | $54.84 | $20.66 |
Typical Hold Time | 62 Days | 61 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
EWH, the iShares MSCI Hong Kong ETF, trades at $22.04, up 2.13% in the last 24 hours. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $21. Recent news highlights volatility in the Hang Seng Index, driven by Federal Reserve decisions and geopolitical tensions. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
The ETF faces headwinds from Hong Kong market weakness and institutional selling, but oversold conditions per RSI may offer tactical opportunities. Risks include ongoing U.S.-China tensions and economic pressures. Investors should weigh exposure to Hong Kong equities against broader market risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →
